Mount Sinai Health System and Memorial Sloan Kettering Cancer Center researchers have developed a new drug delivery approach that uses nanoparticles to enable more effective and targeted delivery of anti-cancer drugs to treat brain tumors in children.
Sean Pinney, MD, FACC, FAST, FHFSA, a top expert in cardiovascular medicine and advanced heart failure and transplantation, has been named Chief of Cardiology at Mount Sinai Morningside. Dr. Pinney will lead all aspects of cardiology at the hospital, including the cardiac catheterization lab and the Al-Sabah Arrhythmia Institute.
Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States. Although highly treatable and preventable, about 140,000 Americans are diagnosed and more than 50,000 people die each year, according to the Centers for Disease Control and Prevention (CDC). The United States Preventative Task Force recommends starting age of screening from 50 to 45.
To celebrate unsung heroes, Mount Sinai Health System has launched a video series that captures the pride and dedication of individuals—many in unassuming roles—who chose a long-term career in health care.
The American Academy of Microbiology has elected Florian Krammer, PhD, Mount Sinai Professor in Vaccinology, and Gustavo Palacios, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, along with 63 peers to its Class of 2023 fellows. Fellows of the American Academy of Microbiology, an honorary leadership group and a think tank within the American Society for Microbiology (ASM), are elected annually through a highly selective peer-review process based on their records of scientific achievement and original contributions that have advanced microbiology.
Not for public release
This news release is embargoed until 23-Feb-2023 11:00 AM EST
Released to reporters: 21-Feb-2023 9:35 AM EST
A reporter's PressPass is required to
access this story until the embargo expires on 23-Feb-2023 11:00 AM EST
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Scientists at the Icahn School of Medicine at Mount Sinai in New York have identified which parts of the immune system go awry and contribute to autoimmune diseases in individuals with Down syndrome.
Researchers from the Icahn School of Medicine at Mount Sinai have generated the first induced pluripotent stem cells (iPSCs) from bats, gaining valuable insights into the close relationship between bats and viruses.
Analyzing the most extensive datasets in the U.S., researchers from the Icahn School of Medicine at Mount Sinai have revealed that vaccination against COVID-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2, the virus that causes COVID-19. The research letter, “Impact of Vaccination on Major Adverse Cardiovascular Events in Patients with COVID-19 Infection,” was published in the Journal of the American College of Cardiology on February 20. The research will also be presented on March 5, 2023 in a poster session in New Orleans, LA, at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology.
Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Genitourinary Cancers Symposium in February.
The Arnhold Institute for Global Health at Mount Sinai has received $8 million from the Arnhold Foundation, enabling doctors, researchers, and students to advance its already-strong base of clinical education programs, training, research, and care services to address the world’s leading health issues and improve global health systems.
Notalgia paresthetica is a common and underdiagnosed condition characterized by a persistent itch in the upper back. To date, there are no FDA-approved treatments specifically targeting this disorder. But a new study, published in the NEJM, suggests that patients with the disorder could potentially get relief with oral difelikefalin.
Medical students at the Icahn School of Medicine at Mount Sinai are challenging a traditional model of medical education they say omits a critical ingredient: preparing students for the experience of segregation within health care.
Seeking to address racism and bias against
Asian Americans and Pacific Islanders (AAPI), as well as the under-representation of AAPI in leadership roles in medicine, Mount Sinai announced today the launch of the Center for Asian Equity and Professional Development (CAEPD). This innovative undertaking represents one of the first of its kind nationwide by an academic medical center.
Mount Sinai researchers have been awarded $12 million over five years by the National Institutes of Health to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis. The Systems Biology of Early Atopy (SunBEAm) Analysis and Bioinformatics Center intends to develop a better understanding of allergy development. The center will apply systems biology to identify early-life markers of risk for food allergies and atopic dermatitis (also known as eczema), as well as biological pathways underlying these common conditions, through the profiling and analysis of longitudinal multi-omics data from a multi-center pre-birth cohort of 2,500 children.
The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai is delighted to announce a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology.
Two separate eye diseases may contribute to age-related macular degeneration (AMD), a leading cause of blindness in the United States, according to a new study from New York Eye and Ear Infirmary of Mount Sinai.
Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD). The research was led by investigators at the Icahn School of Medicine at Mount Sinai. Utilizing these innovative methods, the investigators discovered a network of cell-to-cell communication driving scarring as liver disease advances. The findings, published online on January 4 in Science Translational Medicine, could lead to new treatments.
Using machine learning and clinical data from electronic health records, researchers at the Icahn School of Medicine at Mount Sinai in New York constructed an in silico, or computer-derived, marker for coronary artery disease (CAD) to better measure clinically important characterizations of the disease.
The Mount Sinai Phillips School of Nursing is celebrating two graduating 2022 classes, August and December, with a total of 150 students. The graduation ceremony will take place on Thursday, December 15, at 4 pm at The Mount Sinai Hospital, Annenberg Building, Stern Auditorium (1468 Madison Ave. NY, NY 10029).
The Dubin Breast Center of The Tisch Cancer Institute at the Mount Sinai Health System celebrated its 12th anniversary with its annual gala on Monday, December 12.
Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer patients. Results from a phase 2 clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) in December.
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped
As medical schools across the country grapple with the arduous process of revising their curricula to be anti-racist, students at the Icahn School of Medicine at Mount Sinai have turned a critical eye on the very textbooks that have trained medical students for years.
Researchers at The Tisch Cancer Institute uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results published in JAMA Network Open in December.
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the publication of new real-world evidence (RWE) in Primary Care and Community Health demonstrating the Company’s KidneyIntelX bioprognostic™ test resulted in changed clinical decision making for patients in the early-stage of diabetic kidney disease (DKD) being cared for within the Mount Sinai Health System’s Population Health Ambulatory Pharmacy and Condition Management programs.
The Icahn School of Medicine at Mount Sinai announced today the appointment of two new Laureates as part of its Biomedical Laureates Program, bringing the total to five appointments for this year and furthering its institutional commitment to broadening faculty diversity and mentorship opportunities.
Past social trauma is encoded by a population of stress/threat-responsive brain cells that become hyperactivated during subsequent interaction with non-threatening social targets. As a consequence, previously rewarding social targets are now perceived as social threats, which promotes generalized social avoidance and impaired social reward processing that can contribute to psychiatric disorders.
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.
The polycystic kidney disease (PKD) Foundation—the only organization in the U.S. dedicated solely to finding treatments and a cure for PKD recently named Mount Sinai Health System as a PKDF Partner Clinic for their desire to support patients with Autosomal Dominant PKD (ADPKD).
The Mount Sinai Health System has officially unveiled its new, state-of-the-art Mount Sinai Phillips School of Nursing (PSON) campus, located at 126th Street and Lexington Avenue.
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study from New York Eye and Ear Infirmary of Mount Sinai.